MedTrace Logo

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

NCT07216105 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2026-04-07

No results posted yet for this study

Summary

This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.

Conditions

Interventions

DRUG

FT836

FT836 drug product is administered as an intravenous infusion on multiple days schedule at treatment cycle.

DRUG

Paclitaxel

IV infusion ; 80 mg/m2 QW; Days -21, -14, and -7

DRUG

Cetuximab

Cetuximab administration will begin on Day -4 at the recommended initial dose of 400 mg/m2 as a 120-minute IV infusion

DRUG

Trastuzumab

trastuzumab administration will begin on Day -4 at an initial dose of 4 mg/kg as a 90-minute IV infusion.

Sponsors & Collaborators

Principal Investigators

  • Brian Dempster · Fate Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-04
Primary Completion
2028-01-31
Completion
2030-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07216105 on ClinicalTrials.gov